HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg ...
3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.
The recent article by Tawbi et al. 1 showed superior progression-free survival with the combination of relatlimab (an anti–lymphocyte-activation gene 3 [LAG-3] antibody) and nivolumab over nivolumab ...
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma ...
Immune checkpoint blockade (ICB) immunotherapy has shown little effectiveness against glioblastoma, but Salk Institute scientists have now shown that in mice models of glioblastoma anti-CTLA-4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results